Clinical trials: psoriasis
Chronic Plaque Psoriasis
A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis
This is an open-label, multicenter study to assess the systemic exposure to calcitriol in the adolescent population. Calcitriol 3µg/g ointment (2 mg/cm² per application) is to be applied twice daily to involved skin (10 - 35% BSA…
- Trial name
- NCT00419666
- Testing
- Calcitriol 3mcg/g
- Where
- 7 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Galderma R&D
Psoriasis
A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of participants with moderate to severe plaque-type psoriasis.
- Trial name
- NCT05645627
- Testing
- IBI112
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Rheumatoid Arthritis, Ankylosing Spondylitis
Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis
In this open-label, multi-center, observational, post-marketing surveillance study, patients with ankylosing spondylitis, psoriatic arthritis, or rheumatoid arthritis received biosimilar etanercept 25 mg twice weekly or 50 mg…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- ASQA (NCT04582084)
- Testing
- Etanercept
- Where
- 10 sites in Iran
- Volunteers
- 583 people
- Sponsor
- AryoGen Pharmed Co.
Psoriatic Arthritis
A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis
This study is designed to assess the efficacy of apremilast, either in monotherapy or with stable methotrexate, on imaging outcomes in adults with active psoriatic arthritis with less than 5 years of disease duration (since…
- Trial name
- MOSAIC (NCT03783026)
- Testing
- Apremilast
- Where
- 36 sites in United States, Austria and 9 more
- Volunteers
- 123 people
- Sponsor
- Amgen
Plaque Psoriasis
Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of 12 weeks of treatment with Apo805K1 in subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01483924
- Testing
- Apo805K1
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- ApoPharma
Chronic Plaque Psoriasis
The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis
The main purpose of this study is to assess the effect of smoking status on the success of Etanercept therapy in patients with moderate-to-severe psoriasis.
- Trial name
- NCT02570750
- Testing
- QUESTIONNAIRE ON SMOKING HABITS
- Where
- 30 sites in Romania
- Volunteers
- 183 people
- Sponsor
- Pfizer
Plaque Psoriasis
Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
The purpose of this study is to evaluate Halobetasol Propionate (HBP) foam, 0.05% in subjects aged 12 through less than 18 years with plaque psoriasis in order to check the safety, the potential to suppress the adrenal glands and…
- Trial name
- NCT03992261
- Testing
- Halobetasol Topical Foam
- Where
- 11 sites in United States, Georgia and 2 more
- Volunteers
- 24 people
- Sponsor
- Mayne Pharma International Pty Ltd
Psoriasis, Plaque Type Psoriasis
MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study was to compare the efficacy, safety and immunogenicity of MSB11022 and Humira® in adult subjects with moderate to severe chronic plaque type psoriasis.
- Conditions
- Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis
- Trial name
- AURIEL-PsO (NCT02660580)
- Testing
- MSB11022, Humira®
- Where
- 76 sites in United States, Bulgaria and 10 more
- Volunteers
- 443 people
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Rheumatoid Arthritis, Ankylosing Spondylitis
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Treatment with tumor necrosis factor (TNF) inhibitors, especially adalimumab, demonstrated an improvement in work productivity in participants with rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01282372
- Volunteers
- 500 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
The purpose of this research study is to compare the efficacy and safety of SCT630 and adalimumab (HUMIRA®) in adults with plaque psoriasis.
- Trial name
- NCT03927352
- Testing
- SCT630, Adalimumab
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sinocelltech Ltd.
Psoriasis
Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers
The study is designed to explore the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers.
- Trial name
- PSORITUS (NCT02362789)
- Testing
- Secukinumab
- Where
- 19 sites in Germany
- Volunteers
- 132 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Psoriatic
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by…
- Trial name
- SOLSTICE (NCT04936308)
- Testing
- Guselkumab
- Where
- 169 sites in United States, Argentina and 12 more
- Volunteers
- 453 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis
This study was conducted to evaluate the safety and tolerability of BOS-475 following single and repeat topical administration to healthy participants (Part A), and to evaluate the safety and tolerability of 42-day repeat topical…
- Trial name
- NCT03960450
- Testing
- BOS-475, Vehicle
- Where
- 3 sites in Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boston Pharmaceuticals
Plaque Psoriasis
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06973291
- Testing
- Zasocitinib, Deucravacitinib
- Where
- 113 sites in United States, Bulgaria and 6 more
- Volunteers
- 606 people
- Sponsor
- Takeda
Psoriasis
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis
This study will examine the safety and efficacy in subjects with moderate to severe psoriasis, as measured by Psoriasis Area and Severity Index(PASI), Body Surface Area (BSA), Dermatology Life Quality Index (DLQI) and other…
- Trial name
- NCT01837420
- Testing
- VB-201 80mg, VB-201 160mg
- Where
- 4 sites in Germany, Israel and 2 more
- Volunteers
- 194 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
Psoriasis
A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis
The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) =…
- Trial name
- GUIDE (NCT03818035)
- Testing
- Guselkumab
- Where
- 90 sites in France, Germany
- Volunteers
- 880 people
- Sponsor
- Janssen-Cilag International NV
Arthritis, Psoriatic
A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium
The study will include a representative sample of 150 patients with active Psoriatic Arthritis (PsA) for whom the treating rheumatologist has decided to begin treatment with apremilast.
- Trial name
- APOLO (NCT03096990)
- Testing
- apremilast
- Where
- 22 sites in Belgium
- Volunteers
- 106 people
- Sponsor
- Amgen
Plaque Psoriasis
A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis
This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis.
- Trial name
- NCT07326813
- Testing
- D-2570 Tablet, BMS-986165 Tablet
- Where
- China
- Volunteers
- 477 people
- Sponsor
- InventisBio Co., Ltd
Psoriasis Vulgaris
LEO 90100 in the Treatment of Psoriasis Vulgaris
The purpose of this study is to investigate whether LEO 90100, calcipotriol and betamethasone are effective in the treatment of psoriasis vulgaris.
- Trial name
- NCT01536938
- Testing
- LEO 90100, Calcipotriol, Betamethasone
- Where
- 33 sites in United States
- Volunteers
- 303 people
- Sponsor
- LEO Pharma
Nail Psoriasis, Nail Damage
Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis
A randomized, double blind, placebo-controlled, unicenter, parallel group study to assess the efficacy, safety and tolerability of a multi-funtion toe nail patch in patients affected by nail fragility, nail mychosis and psoriasis…
- Conditions
- Nail Psoriasis, Nail Damage, Mycosis
- Trial name
- NCT07029516
- Testing
- Cosmetic patch containing urea applicated daily for 3 months
- Where
- Italy
- Volunteers
- 72 people
- Sponsor
- Wooshin Labottach Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.